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Abstract— In this paper, we describe a dataset relating to 
cellular and physical conditions of patients who are 
operated upon to remove colorectal tumours. This data 
provides a unique insight into immunological status at the 
point of tumour removal, tumour classification and post-
operative survival. Attempts are made to cluster this dataset 
and important subsets of it in an effort to characterize the 
data and validate existing standards for tumour 
classification. It is apparent from optimal clustering that 
existing tumour classification is largely unrelated to 
immunological factors within a patient and that there may 
be scope for re-evaluating treatment options and survival 
estimates based on a combination of tumour physiology 
and patient histochemistry. 
I. INTRODUCTION 
olorectal cancer is the third most commonly diagnosed 
cancer in the world. Colorectal cancers start in the 
lining of the bowel and grow into the muscle layers 
underneath then through the bowel wall [3]. TNM staging 
involves the Classification of Malignant Tumours  
 
• Tumour (T).  Size of the tumor and whether it has 
invaded nearby tissue  
• Nodes (N). The extent to which regional lymph nodes 
involved  
• Metastasis (M). This is the spread of a disease from one 
organ or part to another non-adjacent organ. 
 
4 TNM stages (I,II,III,IV) are generated by combining 
these three indicator levels and are allied with increasing 
severity and decreasing survival rates. 
 
Treatment options include minor/major surgery, 
chemotherapy, radiotherapy but the correct treatment is 
heavily dependent on the unique features of the tumour 
which are summarised by the TNM staging. Choosing the 
correct treatment at this stage is crucial to both the patients 
survival and quality of life. A major goal of this research is 
to automatically optimize the treatment plan based on the 
existing data. 
The data for this research was gathered by scientists and 
clinicians at City Hospital, Nottingham. The dataset we use 
here is made up of the 84 attributes for 462 patients. The 
attributes are generated by recording metrics at the time of 
tumour removal, these include: 
 
• Physical data (age, sex etc)  
• Immunological data (levels of various T Cell subsets)  
• Biochemical data (levels of certain proteins) 
• Retrospective data (post-operative survival statistics)  
• Clinical data (Tumour location, size etc).  
 
In the research into the relationship between immune 
response and tumour staging there has been some support 
of the hypothesis that the adaptive immune response 
influences the behavior of human tumors. In situ analysis of 
tumor-infiltrating immune cells may therefore be a valuable 
prognostic tool in the treatment of colorectal cancer [7]. 
The immune and inflammation responses appear to have a 
role to play in the responses of patients to cancer [8] but the 
precise nature of this is still unclear.  
 
The goal of this research is to assess the clustering behavior 
of this dataset to see how best the data can be grouped, how 
many clusters it should be grouped into and what these 
clusters represent. It is hoped that this may eventually help 
clinicians to decide how best to treat patients based on their 
biological, chemical and physical attributes at the time of 
tumor resection . Clustering is the act of assigning a set of 
n- dimensional attribute sets to clusters so that the members 
of one cluster are more similar to each other than to those 
in other clusters. If we define how patients can be optimally 
clustered into groups and how many groups they should 
clustered into, we can then assess how well these clusters 
match to key metrics such as survival and physical tumour 
grading. 
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This paper solely discusses unsupervised methods to 
represent the dataset. By removing supervised guidance we 
are allowing for undirected analysis of the data to inform us 
of features that may otherwise be missed. We have made a 
parallel effort to perform supervised modeling but this 
beyond the scope of this paper. Supervised efforts on 
cancer biomarker datasets have previously shown 
interesting relationships in the data and a phenomena called 
“Anti-learning” where testable feature detection using 
standard learning methods appears impossible when 
modeling of low sample sizes in high dimensional feature 
spaces is attempted [1,2]. 
. 
II. DATA ANALYSIS 
The dataset supplied is a biological dataset and as such 
has a rich complement of preprocessing issues. 11.32% of 
the values are missing, with some attributes having over 
40% missing values and some patients having over 30% 
missing values. Saying this, it is still an invaluable record 
of an extensive set of attributes from a relatively large 
number of patients. 
Missing data poses a problem for most modelling 
techniques. One approach would be to remove every 
patient or every attribute with any missing data. This would 
remove a large number of entries, some of which only have 
a few missing values that are possibly insignificant. 
Another approach is to average the existing values for each 
attribute and to insert an average into the missing value 
space. The appropriate average may be the mean, median 
or mode depending on the profile of the data.   
Much of the data takes the form of human analysis of 
biopsy samples stained for various markers. Rather than 
raw cell counts or measurements of protein levels we are 
presented with thresholded values. For instance, CD16 is 
found on the surface of different types of cells such as 
natural killer, neutrophils, monocytes and macrophages. 
The data contains a simple 0 or 1 for this rather than a 
count of the number of cells. This kind of manual 
inspection and simplification is true for most of the data 
and any modeling solution must work with this limitation.  
It is apparent that there are some existing strong 
correlations in the data. By using a combination of 
correlation coefficients and expert knowledge the data was 
reduced down to a set of ~50 attributes.  This included 
removing several measurements that were hindsight 
dependent (ie. chemo or radio treatment) and correlated 
with TNM stage. (ie. Dukes stage).  
Single attribute relationships exist within the dataset but 
are not strong. Analysis of single attributes can yield a 
greater than 65% prediction rate when attempting to predict 
which TNM stage a patient was classified as but only ~55% 
when the TNM stages were restricted to the more 
interesting  (TNM stage 2 or 3). If we look at CD59a and 
CD46 threshold values we can see that they are loosely 
related to survival (figure 1) with elevated levels of each 
indicating a reduction in survival averaging ~13 and 6 
months. (Fig. 1a and b)  
 
 
Figure 1a. Relationship of  CD59 to survival with average survival rates. 
 
 
Figure 1b. Relationship of  CD46 to survival with average survival rates. 
III. UNSUPERVISED LEARNING AND OPTIMAL CLUSTER 
NUMBERS 
We initially look at how TNM stages are represented in 
the whole dataset when it is optimally clustered using a k-
means approach [4]. This aims to divide multidimensional 
data into k clusters where each data point belongs to the 
cluster with the nearest mean. We quickly see that 
clustering based on biochemistry and physical attributes 
does not classify patients into the same classes as the TNM 
stages. Table 1 is a truth table for TNM stages 2 and 3 and 
a 2 cluster k-means approach showing that each cluster has 
a very similar number of patients that were TNM stage 2 
and 3. 
 
Table 1. Relationship of patients of 2 TNM categories to a 2 
cluster k-means approach 
 
TNM Catagory 
Cluster 2 3 
1 24.62% 23.10% 
2 28.27% 24.01% 
 If we look at the survival rates for patients in each of the 
2 clusters we see there is very little difference at averages 
of 41.75 and 41.98 months respectively, as opposed to 
46.78 and 36.36 months for TNM stage 2 and 3 patients 
respectively. This would suggest that when we optimally 
cluster the biochemical data into 2 clusters, membership of 
the resulting clusters is a poor indicator of survival. 
 
If we look at optimal 3 and 4 cluster solutions we get a 
much wider difference in survival periods for each cluster. 
Average survival periods for the three cluster solution were 
39.56, 40.89 and 44.29 months and for the 4 cluster 
solution were 36.87, 40.15, 41.43 and 46.68 months. The 
TNM stages in each cluster are evenly spread suggesting 
survival can be predicted as well based on the biochemical 
marker combinations as the TNM stages. Figure 2a and 2b 
shows 2 of the 4 clusters, cluster 2 has the lowest survival 
rate at 36.87 months and cluster 4 has the highest survival 
rates at 46.68 months. If we look at the most widely 
differing attributes we can see that there are strong 
differences in the representation of these attributes in each 
cluster when compared to the average. To put this into 
context, nearly 60% of patients in cluster 2 had an elevated 
level for FLIP while only 21% of patients in cluster 4 had 
elevated levels of FLIP. FLIP is a key regulator of 
colorectal cancer cell death [10] so this wouldn’t be 
surprising as the presence of it in patients may indicate 
more aggressive tumours. 
 
 
Figure 2a. Mean values for key markers in cluster 2 (low survival rates) 
and cluster 4 (highest survival rates) 
 
Figure 2b. Mean values for key markers in cluster 2 (low survival 
rates) and cluster 4 (highest survival rates) 
 
IV. CLUSTER ANALYSIS OF DATASETS 
 
Using research by Soria et al [5] as a basis we attempted 
to discover the optimal number of classes patients with 
different TNM stage tumours should be classified into. We 
had been largely unsuccessful in classifying patients into 
their TNM stages based on their attribute measurements 
and one possible reason for this is that the patients actually 
belong to 3 or more classes and attempting to classify them 
in a binary way resulted in poor performance. 
In particular we implement a shorter version of the 
algorithmic framework, proposed by Soria et al [9], which 
combines different clustering algorithms and, with the use 
of Validation Indices, tries to define the optimal number of 
classes that describe the dataset. After this a method called 
Consensus Clustering is used to define the classes. The 
proposed framework consists of up to 7 steps, of which we 
will use the first 4, these are: 
1. Preprocessing : This step includes the deletion of rows 
which contain missing values, data transformation and the 
calculation of descriptive statistics. 
2. Clustering : In this step various clustering algorithms 
are applied to the dataset including Hierarchical Clustering, 
K-means, PAM and Fuzzy C-means. 
3. Validation : In this step the utilisation of validation 
indices helps us to find the optimal number of clusters 
when this number is not known before the analysis. 
4. Visualization & Agreement : In this step we obtain a 
general characterisation of the cluster analysis we 
performed here through various plots  
 
We began by taking a small subset of the data that had 
very few missing values (~0.5%) and only pertained to 
TNM stage 2 and 3 patients, replacing any missing values 
with the modal value. The main aim here was to define how 
many clusters would be required to classify the data 
optimally and if the resulting clusters resembled the TNM 
staging. A k-means clustering approach was then used on 
the dataset to optimally cluster the data into 2-15 clusters. 
Each of these clustering approaches was then tested to see 
how well the clusters fitted using 6 clustering indices to 
score them [6]. Results shown in figure 3 show that 3 or 4 
clusters appears to be optimal for all 6 Indexes 
We then ranked the performance of the six cluster 
indexing approaches for 2 to 10 clusters and calculated a 
value to represent performance using the reciprocal of the 
average ranking performance, with and without the 
Friedman Index (this index appeared to be the least 
reliable). The results from this (figure 4) would suggest that 
patients with TNM stage 2 and 3 tumours should be 
separated into 3 or 4 groups based on their immunology 
and chemistry statistics. 
 
 
 
 
Figure 3. Cluster Optimality as defined by 6 cluster index calculations 
 
 
 
 
 
Figure 4. Ranking calculation for 2 – 10 clusters 
 
If we look in more detail at the cluster membership we can 
get an idea about how attributes are divided up into 
3clusters (table 2). Discussing the role of each abbreviated 
attribute presented here is beyond the scope of this paper 
but it includes levels for various immune cell subsets (eg. 
CD68), tumour suppression proteins (eg. P53) and degree 
of mutation in sections of DNA (MSI). These results 
continue to confirm that the patients are optimally 
separated into greater than 2 groups based on their 
immunohistochemistry. 
 
 
 
Table 2. Levels of cell markers for each cluster as a percentage 
above (+) or below (-) average 
 
 
Cluster 1 Cluster 2 Cluster 3
CD68 -38.03 -9.09 44.59
vegfc -26.89 -9.28 34.23
micahilo -25.37 17.39 7.55
apcMHC2 -4.81 -21.16 24.57
p53 17.42 -24.09 6.32
ulbp3rec -15.04 -10.01 23.71
ulbp1rec -13.07 -11.81 23.55
CD16 -5.43 -18.01 22.19
bcl2 1.41 -17.46 15.20
DR4 -1.31 16.29 -14.19
msi -15.01 2.60 11.74
p27nuc -13.16 4.45 8.25
ulbp2rec -10.63 -3.08 12.96
mhc -11.59 2.25 8.83
FLIP -11.41 2.43 8.50
cd46 8.47 -4.11 -4.13
p27cyto -6.42 -1.39 7.39
stat1nuc2 0.62 -4.41 3.59
ki67 -1.61 -2.87 4.23
cd59a -4.05 0.99 2.89
mhcallele 0.92 2.17 -2.92
  
 
 
Next we look at the relationship between the inclusion of 
missing values with predicted number of clusters. We have 
reported in detail the findings from two processed datasets 
that point to the data being optimally clustered into 3 
datasets. In this section we analyse this finding further to see 
how the optimal number of clusters changes with dataset 
size and if there is any effect of adding data from patients 
with TNM stage 1 and 4 tumours 
 
 
Figure 5. Optimal cluster number using different patient subsets. 
 
If we reduce the number of patients based on removing those 
with the most missing data points first, and then look at the 
optimal number of clusters for each resulting dataset we see 
a graph that suggests 3 or 4 clusters solutions are optimal for 
datasets with just TNM stage 2 and 3 tumours (figure 5).. 
This would suggest that the TNM staging may not a 
powerful reflection of physical and biochemical conditions 
of a patient at the time of operation. 
 
We can also look at the effect of removing attributes from 
the dataset one at a time based on missing values and seeing 
how this affects the optimal number of clusters for both the 2 
and 4 TNM scenarios (Figures 6a and 6b). These show that 3 
clusters to be most optimal, especially in the range of 25-35 
attributes. This may be the most important range given that 
higher than this many more attributes with a high percentage 
of missing values are included and lower than 25 starts to 
exclude more and more important attributes. Overall it is 
shown that a dataset classified into 2 groups based on 
physical characteristics of the tumour does not agree with 
classification based on immune-histochemical data.   
 
 
Figure 6a. Optimal number of clusters using consensus clustering for 
TNM 2,3 
 
Figure 6b. TNM 1,2,3,4 tumour patients with an increasing number of 
attributes 
 
 
V. CONCLUSIONS 
We have presented results for a unique dataset based on 
the biochemical and factors associated with colorectal 
tumour patients. This dataset is limited in many ways, but 
extremely important nonetheless and understanding any 
relationships or features based on the dataset to hand is an 
urgent priority. Currently, the most important guide to post-
operative treatment is the TNM grading of the removed 
tumour. We argue here that TNM grading may not be 
aligned to the biochemical status of the patient. Given that 
the ongoing treatment for a patient immediately after tumor 
resection is directly acting upon a patients biochemistry it 
could be argued that an understanding of this 
  
 
 
immunological, biological and chemical status of the patient 
is at least as important as the physical characteristics of the 
tumour. 
 
It is apparent that when clustering into 2 groups based on 
a selection of biochemical and physical characteristics is a 
poor representation of the patient state. There is no 
relationship between the new clusters and survival or TNM 
stage. This could be argued another way that 2 TNM stages 
for these patients is a poor representation of their 
biochemical status. When the number of clusters is 
examined it seems apparent that 3 or 4 clusters is optimal for 
patients, regardless of if they are from 4 TNM stages or just 
the most ambiguous TNM stage 2 and 3 group. Again, this 
would suggest that TNM staging is a poor representation of 
patients biochemical state.  
 
The fact that prediction of survival can be achieved at 
comparable rates to TNM staging for 2 of the groups 
(36.67|36.87 and 46.68|46.78) suggests that survival is 
actually based on BOTH the physical metrics used for TNM 
staging AND the biochemical and immunological markers 
presented at the time of tumor resection. 
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